Drug Type Small molecule drug |
Synonyms (±)-bevantolol, 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol, 1-(3,4-dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol + [17] |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers), VMAT2 inhibitors(Synaptic vesicular amine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (31 Mar 1995), |
RegulationOrphan Drug (US) |
Molecular FormulaC20H28ClNO4 |
InChIKeyFJTKCFSPYUMXJB-UHFFFAOYSA-N |
CAS Registry42864-78-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01369 | Bevantolol Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 31 Mar 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 2 | ES | 08 Aug 2018 |
Phase 2 | 32 | sfaszgehnk(lzfwpdnoyj) = The most frequent adverse events during SOM3355 administration were mild to moderate zqanlntimm (zjcfrugdlv ) | - | 09 Dec 2022 | |||
Phase 2 | 32 | pwzwhzjecz(nlmpyykinl) = yooggobgyn iwagmewrdf (peldbfrqxe ) | Positive | 04 Oct 2021 | |||
Placebo | - |